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Abstract 
Human population growth and rising income levels in developing countries are increasing demand for animal pro-
tein. One of the key enablers of the associated increase in global animal protein production has been biotechnology, 
defined as, “any technological application that uses biological systems, living organisms or derivatives thereof to make 
or modify products or processes for specific use.” Biotechnologies have directly benefitted the three core scientific 
disciplines of animal science—genetics, nutrition, and health. Significant potential remains to use biotechnologies to 
improve animal health. Globally, more than 20 % of animal protein is lost as a result of disease. A number of diseases 
have been targeted by using recombinant DNA (rDNA) techniques in the breeding process to develop disease-
resistant food animals, although no such animals have yet been approved anywhere in the world. Part of the reason 
for this is that “modern” biotechnologies involving the use of rDNA are subject to a unique set of governance and 
regulatory requirements under the Cartagena Protocol on Biosafety and other national regulatory frameworks. The 
Protocol defines “modern biotechnology” as the application of in vitro nucleic acid techniques, including recombinant 
deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles, or fusion of cells beyond the 
taxonomic family, that overcome natural physiological reproductive or recombination barriers and that are not tech-
niques used in traditional breeding and selection. In considering the impact of this modern biotechnology trigger for 
additional governance and regulatory oversight, a case study is presented of the various biotechnological approaches 
that might be employed to address the important tropical disease problem of African trypanosomiasis. Some 
approaches involve the use of natural gene drive systems (“selfish” gene elements that skew inheritance in their favor) 
and irradiation-induced sterile insect technique. Others involve techniques that trigger the modern biotechnology 
definition and include the use of an rDNA-derived paratransgenesis, a strategy that employs symbiotic microbes to 
control pathogens in vector populations, and the development of genetically engineered trypanosomiasis-resistant 
cattle. Despite the fact that all of these approaches are associated with potential harms and potential benefits, only 
those that involve the use of modern biotechnology such as rDNA techniques are subject to exceptional regulatory 
requirements. Triggering governance and regulatory oversight based on an arbitrarily-defined subset of techniques 
rather than on the outcomes or products resulting from the use of those techniques, does nothing to address the 
potential harms that might be associated with non-governed processes and disadvantages governed technologies 
with unique regulatory burdens. Even-handed evaluation that agnostically weighs the potential benefits and risks of 
products rather than the techniques used to produce those products is essential to ensure that the biotechnology 
best suited to addressing a problem can be employed, rather than a potentially less efficient approach that is chosen 
solely because it avoids the complicated regulatory frameworks that are uniquely triggered by the use of a modern 
biotechnology.
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Background
On current trends, the United Nations Food and Agri-
culture Organization (FAO) projects that there will be a 
73 percent increase in meat and egg consumption and a 
58 percent increase in dairy consumption [1] over 2011 
levels worldwide by the year 2050. Already, global meat 
production has more than doubled since 1970, increasing 
from 120 million tonnes to more than 270 million tonnes 
in 2010. Similarly, dairy production in the same period 
rose from 400 million tonnes to 690 million tonnes [2]. 
This change in production resulted both from dramatic 
improvements in the amount of product per animal due 
to genetic selection and improved nutrition [3], and 
increases in the sizes of animal populations. This lat-
ter point is perhaps most clearly illustrated by the fact 
that between 1980 and 2010 the world’s population of 
chickens increased almost threefold, from 7.21 to 19.60 
billion head [4]. For other livestock species, the current 
global populations are estimated to be 1.43 billion cat-
tle, 1.87 billion sheep and goats, and 0.98 billion pigs [5]. 
One important driver for this dramatic increase in ani-
mal numbers and animal protein production, termed “the 
livestock revolution” [6], is growing demand for milk, 
meat and eggs. Two main forces are driving this demand 
for animal protein: human demographics and economic 
development.
Alongside the global livestock population, the world’s 
human population has grown exponentially, from about 
4 billion people in 1975 to more than 7 billion today. By 
2050, this number is expected to rise to approximately 9.6 
billion [7]. Paralleling the human population growth, the 
world economy has also been growing dramatically over 
recent decades, with a 20-fold increase in global gross 
domestic product between 1970 and 2012 [4].
As incomes rise in developing economies, especially 
among traditionally undernourished populations, an ini-
tial increase occurs for dietary calorie intake of all food 
products equally, and then transitions to a decrease in 
per capita consumption of cereals and vegetables cou-
pled with an increase in consumption of sugar, fats and 
animal products. This transition can lead to improved 
health because the overall nutritional value of animal 
protein is higher than that of staple foods such as cere-
als, roots and tubers. It has been shown that even small 
amounts of animal products can correct amino acid defi-
ciencies in cereal-based human diets [8]. Consumption of 
milk and other animal-source foods by undernourished 
children improves anthropometric indices (weight-for-
height, height-for-age and weight-for-age) and cognitive 
function and reduces the prevalence of biochemical and 
micronutrient deficiencies, reducing morbidity and mor-
tality [9]. Animal source proteins are also more digest-
ible and metabolized more efficiently than plant proteins, 
meaning they are more rapidly and readily available for 
use [10]. In one report, the consumption of meat was 
associated with a 36 % decrease in the likelihood of stunt-
ing among toddlers (12–24 months) living in Guatemala, 
Democratic Republic of Congo, Zambia, and Pakistan 
[11]. This shift of food consumption patterns in develop-
ing countries towards livestock products is a major factor 
to be considered in the growth of world agriculture.
The importance of animal disease
It is interesting to note that developing economies actu-
ally produce more meat and milk than developed econ-
omies. However, this supply is still insufficient to meet 
demand due to the fact that much of the growth in the 
world’s population and in incomes is also occurring 
in developing economies. Animal system productivity 
within developing regions is generally less than in devel-
oped countries owing to a combination of factors includ-
ing inadequate animal nutrition (as a consequence of low 
feed quality, quantity and lack of nutritionally-balanced 
diets), lack of access to genetic selection techniques, and 
higher incidence of livestock disease [3]. Developing 
economies are faced with a number of human, zoonotic 
(can be transmitted between animals and humans) and 
livestock diseases, creating a major impediment to both 
economic development and food safety [4]. The World 
Organization for Animal Health (OIE) estimates that 
worldwide an average of more than 20 % of animal pro-
tein is lost as a result of disease; therefore, significant 
potential exists to reduce this loss thereby decreasing the 
overall environmental impact per unit of animal protein 
production through improving the health of global live-
stock populations.
The widespread occurrence of animal disease in devel-
oping economies is one of the major factors negatively 
impacting livestock productivity in these countries. 
Generally, these diseases have the greatest impact on 
resource-poor livestock farmers and effective disease 
control is essential for poverty alleviation. Due to the 
devastating effects of disease on local livestock popula-
tions, many developing economies, particularly in sub-
Saharan Africa, are net importers of livestock products. 
As a result, imports of livestock products from developed 
to developing economies are increasing. This is in part 
due to the fact that exports are confined to countries with 
officially confirmed and carefully monitored disease-free 
status and the absence of disease agents that are notifi-
able to the OIE. The net effect of these trends is that poor 
producers in some developing economies are unable to 
participate in supplying the domestic demand in their 
countries due to the prevalence of endemic animal dis-
eases. Embracing solutions such as those afforded by var-
ious biotechnologies to prevent disease will be necessary 
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to break this cycle of the economic effects of animal dis-
eases and enable producers to participate in their local 
economies. This review will focus on the opportunities 
that biotechnologies offer to address some of the most 
pressing disease problems of animal agriculture and the 
use of these tools in meeting the global demands for ani-
mal protein.
The role of biotechnology in animal production
One of the key enablers of the increased global produc-
tion of animal protein is biotechnology, which is defined 
by the Convention on Biological Diversity [12], as “any 
technological application that uses biological systems, 
living organisms or derivatives thereof to make or mod-
ify products or processes for specific use”. The three core 
disciplines of animal science—genetics, nutrition, and 
health—have all benefited from a variety of biotechno-
logical developments. Included under this broad head-
ing are some relatively common and non-controversial 
biotechnologies such as artificial insemination (AI), use 
of genetic markers in breeding programs, feed additives, 
molecular diagnostics and vaccines. Others, such as clon-
ing and the use of recombinant DNA (rDNA) technology 
to make transgenic or genetically engineered (GE) ani-
mals, recombinant vaccines and GE insects, have been 
associated with considerable controversy and often face 
both political and public opposition.
To date, the vast majority of biotechnologies have 
been produced and implemented in developed coun-
tries. However, various examples illustrate the potential 
of these approaches to improve health and productivity 
in livestock production systems and help reduce pov-
erty and hunger in developing countries. The global 
elimination of Rinderpest (cattle plague) was achieved 
through a large-scale vaccination and surveillance pro-
gram [13]. The sterile insect technique (SIT) has been 
used to suppress and locally eradicate or prevent the 
invasion of New World and Old World screwworms 
in North America (US), Netherlands, Central America 
and Libya [14]. The 2013 U.N. Food and Agriculture 
Organization (FAO) report, “Biotechnologies at Work 
for Smallholders: Case Studies from Developing Coun-
tries in Crops, Livestock and Fish,” details 19 case stud-
ies in which agricultural biotechnologies were used to 
serve the needs of smallholders in developing countries. 
Among these was the application of SIT in Zanzibar to 
eradicate tsetse flies, the vector of trypanosomiasis. A 
common component of these successful programs has 
been global collaboration and investment by interna-
tional organizations such as as the FAO, OIE, Interna-
tional Atomic Energy Agency (IAEA) and the World 
Health Organization (WHO), along with national politi-
cal commitments.
These examples only provide a glimpse of the tremen-
dous growth that has taken place in the fields of molecu-
lar genetics and genomics since the 1980s, and a range 
of DNA-based technologies are likely to play an increas-
ingly important role in making future animal produc-
tion more efficient, economical and sustainable. Some 
emerging rDNA-based technologies have the potential 
to address long-standing animal health issues that have 
proven intractable using traditional approaches. These 
technologies include GE animals that have been exten-
sively reviewed elsewhere [15]. However, they are being 
deliberated in an often contentious global setting that 
includes the voices of many players, including the various 
bodies that are involved with international governance of 
animals and animal products, biosafety protocols, multi-
national animal activist and environmental corporations, 
and trade partners. Biotechnologies are increasingly 
being evaluated based not only on their technical effec-
tiveness and feasibility, but also on their broader ethical 
and social implications, and this can lead to disagree-
ments among interested parties depending upon their 
values and visions for a desirable future. It is important to 
employ the most suitable innovations, and in cases where 
that means rDNA technologies, it is becoming increas-
ingly evident that evaluations need to be conducted in a 
manner that is agnostic to the technology used to achieve 
the result and focus on the unique risks and poten-
tial benefits that are associated with the end product or 
outcome.
Reducing livestock susceptibility to infectious diseases 
would seem to be a goal that aligns with most defini-
tions of sustainability. Such a goal would improve animal 
welfare, decrease production losses and the use of thera-
peutic interventions such as antibiotics, and improve 
production efficiency. In fact, the goal of many tradi-
tional breeding programs in both plants and animals is to 
decrease host susceptibility to pests and disease. This tar-
get has been the ambitious goal of animal genetic engi-
neers [16, 17] since the first GE livestock were generated 
almost 30 years ago [18]. In general, disease-resistant GE 
farm animals can be generated by either the introduction 
of resistance genes into the genome of the host (gain-
of-function strategy) or the targeting of endogenous or 
exogenous susceptibility genes (loss or exchange-of-
function strategy) [19]. There are many extant exam-
ples where researchers have successfully modified the 
genomes of livestock to render them less susceptible to 
disease (Table 1). Despite these technical successes, there 
are currently no GE animals approved for food purposes 
anywhere in the world. Conversely, GE plants, which 
were first produced in 1983 [20], were approved for food 
purposes in the 1990s and have been rapidly adopted by 
farmers globally. Approximately 180 million hectares 
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of GE crops (13  % of total arable land) were cultivated 
worldwide by 18 million farmers in 2014. Of these farm-
ers, 94  %, or more than 17 million, were small acreage 
and resource-poor farmers in developing countries [21].
Regulation of animal biotechnologies
Part of the reason for the slow development of GE ani-
mals is that their potential deployment is associated 
with a daunting range of regulatory oversight and gov-
ernance requirements from local and national govern-
ments, and international organizations. Globally, the 
Cartagena Protocol on Biosafety to the Convention on 
Biological Diversity (Protocol) is the preeminent instru-
ment for the regulation of the products of GE technol-
ogy at the international level. The stated objective of the 
Protocol relates to “the conservation and sustainable use 
of biological diversity”, which may be adversely affected 
by the trade (or “transboundary movements”) of “living 
modified organisms”. “Biological diversity” (or biodiver-
sity) refers to the number and variety of living organisms 
on the planet and is defined in terms of genes, species 
and ecosystems. The Protocol aims to ensure the safe 
handling, transport and use of living modified organ-
isms (LMOs), both plants and animals, that ‘‘may have 
adverse effects on the conservation and sustainable use 
of biological diversity, taking also into account potential 
harms to human health’’, with specific focus on trans-
boundary movements. The Protocol defines an LMO as 
any living organism that possesses a novel combination 
of genetic material obtained through the use of ‘‘modern 
biotechnology’’, which is defined as: (a) in  vitro nucleic 
acid techniques, including recombinant deoxyribonucleic 
acid (DNA) and direct injection of nucleic acid into cells 
or organelles, or (b) fusion of cells beyond the taxonomic 
family that overcome natural physiological reproductive 
or recombination barriers and that are not techniques 
used in traditional breeding and selection. The Cartagena 
Protocol is therefore limited to the subset of biotechnol-
ogy encompassed by the term “modern biotechnologies.” 
Likewise, many national regulations are triggered by the 
use of rDNA technologies.
The United States of America (US) is not a party to 
the Cartagena Protocol. However, the trigger for the 
mandatory US Food and Drug Administration (FDA) 
regulation of GE animals is specified as those animals 
modified by rDNA techniques, including the entire lin-
eage of animals that contain the modification. All GE 
animals are captured under these provisions, regardless 
of their intended use. Thus, although the regulatory 
evaluation is based on the product (the GE animal), 
the method used to produce the genetic change (i.e. 
rDNA versus other breeding methods) is the trigger for 
regulatory oversight. The fast-growing GE AquAdvan-
tage salmon is the first GE animal to be evaluated by 
the FDA for food purposes. University researchers first 
produced the founder line for this strain in 1989 [22]. 
Despite the fact that the product has undergone nearly 
two decades of FDA regulatory scrutiny and the com-
pany has spent more than $77 million on development 
and regulatory costs, no decision regarding the appli-
cation to commercialize this fish had been made as of 
October 2015. Much of this delay has been associated 
with political interference in the science-based regu-
latory review [23]. In contrast, there is no regulatory 
oversight of the many lines of fast-growing livestock 
species, including fast-growing Atlantic salmon, that 
have been produced using conventional selection and 
breeding techniques.
A case study: African trypanosomiasis
In considering the impact of “modern biotechnology” or 
“rDNA” triggers for additional governance and regula-
tory oversight of biotechnological tools to address ani-
mal disease, a case study is presented of biotechnological 
approaches that might be employed to address the major 
tropical disease African trypanosomiasis. This disease, 
caused by blood parasites of the genus Trypanosoma that 
are transmitted by tsetse flies, affects human health, live-
stock production, agricultural production (lack of draught 
animals and manure), rural socio-economic development, 
national economies (import and export of animal prod-
ucts), and the environment (insecticide and trypanocide 
applications). The WHO estimates that there are currently 
10,000–45,000 cases of human African trypanosomiasis 
(HAT), with 60 million people at risk in 36 African coun-
tries. Without treatment, infection is almost always fatal.
Table 1 Examples of  successful modification of  livestock 
genomes to render them less susceptible to disease
Disease Species References
African swine fever pigs [47]
Avian influenza chickens [48]
Avian leukosis virus chickens [49]
Bacteria resistance sheep/pigs/fish [50–53]
Bovine spongiform encephalopathy cattle, sheep [54, 55]
Bovine tuberculosis cattle [56]
Foot and mouth disease various [57]
Grass carp haemorrhage virus (GCHV) fish [58]
Influenza A & classical swine fever pigs [59]
Mastitis/health of nursing offspring various [60–65]




Visna virus resistance sheep [67]
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Losses in livestock production due to African animal 
trypanosomiasis (AAT), or nagana, are estimated at US 
$1 billion annually [24]. Direct losses in meat production 
and milk yield, plus the costs for trypanosomiasis con-
trol programs, are estimated at up to US $1.2 billion each 
year. In many parts of sub-Saharan Africa (Fig.  1), the 
presence of tsetse flies is considered the major obstacle 
to the development of more efficient and sustainable live-
stock production systems and is one of the most impor-
tant causes of hunger and poverty.
Current methods of controlling trypanosomiasis and 
the tsetse fly include: (1) SAT (sequential aerosol tech-
nique), an aerial application of extremely low volumes of 
nonresidual insecticides, (2) stationary bait techniques, 
i.e. use of insecticide-impregnated targets and traps that 
can be odor-baited, (3) the live bait technique, i.e. appli-
cation of residual insecticides on livestock, (4) SIT (sterile 
insect technique), i.e. the release of sterile male insects, 
and (5) treatment of cattle with trypanocidal drugs [25]. 
The treatment of livestock with trypanocides and insec-
ticides is associated with high costs, and resistance is 
developing to these pesticides and trypanocides. Due to 
the lack of effective vaccines (due to the high rate of anti-
genic variation by these blood parasites) and  affordable 
drugs, vector control currently remains the most efficient 
strategy for sustainable disease management.
An example of this is the successful eradication of the 
tsetse population on Unguja Island (Zanzibar) using an 
area wide integrated pest management (AW-IPM) cam-
paign. With a disease prevalence of 19 %, the rural farm-
ing communities were unable to maintain livestock as a 
basis for farming, food production, or income-generation 
prior to the program. The fly population was initially sup-
pressed using insecticide-based control strategies. SIT 
was used as an important final component of the cam-
paign to drive the population to extinction [26].
Following eradication, increases in livestock and crop 
productivity and animal availability for transport and draft 
purposes [26] resulted in substantial social and economic 
improvements. A 30  % increase in yearly average income 
over 1999 levels was recorded in 2002. Demand increased for 
improved livestock breeds and the number of farmers raising 
improved cattle breeds increased from two percent in 1985 
to 24 percent in 2002. During the same period, milk pro-
duction nearly tripled and the proportion of farmers selling 
milk from indigenous cattle increased from 11 to 62 percent. 
Households with a monthly income of over US $25 increased 
from 69 to 86 percent; and those with a monthly income of 
over US $50 increased from 22 to 36 percent.
The project budget was approximately US $3.5 million 
over 4 years. An additional US $2 million included sub-
stantial insectary refurbishment, operational research, 
and many other activities including the need to establish 
large tsetse fly populations due to the reduced fitness of 
the males after irradiation, a facility to irradiate the males, 
and the weekly expenses involved with releasing sterile 
males. The successful eradication involved a substantial 
investment, but costs must be weighed against the many 
benefits obtained so far and those that are expected in 
the future, and against the cost of permanently invest-
ing in continuous suppression based on insecticides. This 
example is seen as a success story in the deployment of 
biotechnology to address an important disease problem.
In spite of these successes using a laboratory colony 
of the target species, efforts to establish mass rearing of 
tsetse colonies from the target field population revealed 
a susceptibility to salivary gland hypertrophy virus 
(SGHV). Despite initial success, the field colony experi-
enced a steady decline over 2  years and collapsed [27]. 
The presence of SGHV in the wild tsetse has become a 
stumbling block for establishing and maintaining colo-
nies for tsetse SIT control. A strategy to manage this 
tsetse virus will be required to continue this program.
As a result of the successes and limitations of SIT to 
date, complementary novel biotechnological approaches 
have recently been proposed and modeled to be sucessful. 
These involve manipulation of the symbiotic bacteria that 
have been found in tsetse flies, including the endosym-
biont Sodalis glossinidius, and the reproductive symbiont 
Fig. 1 Major cattle production areas and tsetse-infested zones in 
Africa. Trypanosomiasis occurs in livestock wherever there are tsetse 
flies. A lower density of cattle is found in tsetse-infested as compared 
to tsetse-free areas of Africa [46]. Used with permission (https://ilri.
org/InfoServ/Webpub/fulldocs/Ilrad82/Trypano.htm)
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Wolbachia pipientis. Wolbachia is an obligatory intra-
cellular and maternally transmitted bacteria that gives 
the female tsetse flies in which it resides a reproductive 
advantage over female flies in which it does not, therefore 
becoming more common over time in the tsetse popu-
lation. In insects, embryonic lethality occurs when an 
infected male is crossed with an uninfected female. This 
lethality rapidly biases inheritance in the population and 
increases the frequency of Wolbachia-infected insects by 
transmitting to the next generation with near 100 % suc-
cess, thereby creating a gene drive system for Wolbachia. 
This naturally occurring gene drive system can be used 
to increase the frequency of other maternally-inherited 
symbionts. Paratransgenesis, a term used to describe an 
insect carrying a GE microorganism typically modified to 
make the insect resistant to the disease-causing organism 
[28], can benefit from gene drive systems to spread the 
GE microorganism within an insect population. Sodalis 
glossinidius is ideally suited as a paratransgenic delivery 
system for anti-trypanosomal components to control 
parasite development in the fly. A strong gene drive sys-
tem increases the power of paratransgenesis to replace 
non-transformed symbionts present in natural vector 
populations.
Another biotechnological approach that could be used 
to address trypanosomiasis would be the development 
of disease-resistant cattle. A consortium of scientists 
from the City University of New York, the International 
Livestock Research Institute (ILRI) in Nairobi, Kenya, 
the Roslin Institute, and Michigan University have been 
awarded a grant by The National Science Foundation of 
the USA and the Bill and Melinda Gates Foundation to 
develop GE cattle that are resistant to African Bovine 
Trypanosomiasis [29]. They plan to build upon work in 
transgenic mice where expression of a baboon trypano-
some lytic factor resulted in sterile immunity (complete 
resistance) to trypanosomiasis [30].
In considering these various biotechnologies, radiation-
induced SIT and the use of a Wolbachia-based invasive 
gene drive system would not be subject to rDNA regu-
lations or the Cartagena Protocol on Biosafety, whereas 
paratransgenesis using GE bacteria, which would per-
haps achieve the same goal of eliminating African tsetse 
and trypanosomiasis more effectively, would be sub-
ject to both. Gene drive was not an issue that was con-
sidered when the terms of the Cartagena Protocol were 
first negotiated. According to the Protocol, an advance 
informed agreement (AIA) procedure applies before the 
first environmental release of GE organisms in another 
country and grants the importing country the right to 
request the exporting country to perform a risk assess-
ment at its own expense, part of which is to determine the 
likelihood of “unintentional transboundary movements”. 
In effect, the Wolbachia-based invasive gene drive system 
carrying the endosymbiont Sodalis glossinidiu would be 
beyond the scope of the Cartagena Protocol. However, if 
Wolbachia-carrying tsetse flies also carried a paratrans-
genic GE endosymbiont bacteria modified to control par-
asite development in the fly they would be covered by the 
Cartagena Protocol. Environmental release would likely 
be disallowed due to the high probability of the same 
“unintentional transboundary movements” associated 
with the Wolbachia-based invasive gene drive system, 
irrespective of the potential disease-control benefits that 
might be associated with the paratransgenic GE endos-
ymbiont bacteria.
Similarly to paratransgenesis, GE cattle would be sub-
ject to the Protocol and, depending upon the country, 
would also likely fall under additional national regula-
tions that may include both human health and environ-
mental risk assessments, and an evaluation of the social 
and ethical implications of the resulting phenotype. 
Although such cattle could be of great benefit to people 
and livestock in the endemic areas through reduced inci-
dence of trypanosomiasis, to livestock producers through 
increased profitability, and to the environment through 
reduced pesticide use, their use could conceivably result 
in an overall decline in biodiversity due to increased live-
stock production in areas that were previously unavaila-
ble due to trypanosomiasis. It is possible that an increase 
in cattle numbers resulting from increased survival could 
lead to detrimental environmental effects such as over-
grazing which has been shown to be a contributor to land 
degradation and desertification. Although it might also 
be argued that there would be a decreased incidence of 
non-productive, chronically-ill cattle and that if farmers 
are confident of stock survival, they might be more will-
ing to invest in improved health and grazing management 
programs. The eradication of the tsetse fly from Zanzi-
bar was associated with an increase in cattle numbers, 
an outcome that was considered one of the benefits of 
the SIT-based eradication program, although the island 
location of this intervention may have limited the pos-
sible impacts  of increased cattle numbers on biodiver-
sity. This seemingly inconsistent appraisal of the impacts 
of biotechnologies developed using rDNA technolo-
gies as compared to those developed using non-rDNA 
approaches is difficult to reconcile from a scientific per-
spective. The potential harms associated with the prod-
ucts derived from rDNA technologies have proven no 
higher than those associated with the use of conventional 
technologies and may be less than those associated with 
existing production systems; and the benefits from these 
technologies are potentially high. It would seem that the 
potential impact of the outcomes of all proposed biotech-
nologies should be evaluated in the context of achieving 
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a balance between the ethical mandate to control disease 
on a global scale, respect for the sovereignty of states, and 
an agnostic evaluation of the potential harms and poten-
tial benefits associated with the outcome that is expected 
to result from a proposed biotechnology in the context of 
existing production systems, irrespective of the technol-
ogy that was used to develop it.
Considerations and complications
To some, addressing the problems of global hunger and 
poverty should be the key and perhaps principle drivers 
of technology adoption, but considerations such as the 
protection of biological diversity or animal integrity can 
complicate the issues. This leads to inherent conflicts 
when a technological approach leads to the destruction 
or detriment of an organism (e.g. a pest) that is causing 
disease or decreased productivity, or  an increase in the 
number of an agricultural species like cattle. While some 
may see that outcome as helping food security, others 
may view it as decreasing biodiversity or subjecting a spe-
cies to an undesirable, unnatural genetic manipulation. 
While both may agree that the technology is effectively 
decreasing the prevalence of the vector, disagreements 
may ensue as to whether this is a desirable outcome 
based on individual values. These differing worldviews 
sometimes play out in regulatory evaluations of modern 
biotechnologies, and although couched as scientifically-
based risk evaluations, factors regarding the desirability 
of the innovation, including ethical and social considera-
tions and not science, often drive regulatory decisions. 
Regulation is increasingly being used to prevent the 
deployment of potentially beneficial biotechnologies 
based on contrasting values and visions for the future.
A 2012 decision in the Philippines regarding the 
introduction of a GM insect-resistant talong (eggplant) 
[through the insertion of a gene from Bacillus thuringien-
sis (Bt)] provides an example of this conflict. In consider-
ing this technological development, the Court of Appeals 
in the Philippines ruled against allowing experiments on 
Bt talong using an argument in support of biodiversity 
[31]; in this case, the biodiversity was represented by a 
species of borers that consume talong. The ruling stated 
“It is a deliberate genetic reconstruction of the eggplant 
to alter its natural order which is meant to eliminate one 
feeder (the borer) in order to give undue advantage to 
another feeder (the humans). The genetic transformation 
is one designed to make Bt talong toxic to its pests (the 
targeted organisms). In effect, Bt talong kills its targeted 
organisms. Consequently, the testing or introduction of 
Bt talong into the Philippines, by its nature and intent, is 
a grave and present danger to (and an assault on) the Fili-
pinos’ constitutional right to a balanced ecology because, 
in any book and by any yardstick, it is an ecologically 
imbalancing event or phenomenon. It is a willful and 
deliberate tampering of a naturally ordained feed-feeder 
relationship in our environment. It destroys the balance 
of our biodiversity. Because it violates the conjunct right 
of our people to a balanced ecology, the whole constitu-
tional right of our people (as legally and logically con-
strued) is violated”. The decision is now on appeal in the 
Supreme Court of the Philippines.
This decision valued avoidance of a potential threat to 
biodiversity by targeting an agricultural pest over poten-
tial benefits associated with the pest-resistant product or 
the fact that pests threaten agricultural production sys-
tems and food security. All agricultural systems involve 
using selected crop and animal varieties and altering the 
species composition of a given ecosystem, presumably 
to the advantage of food production and human “feed-
ers” and to the disadvantage of pests, weeds, and less 
productive food species. Frequently, agricultural tech-
nologies associated with pest control are controversial. 
Herbicides, insecticides, fungicides and antibiotics are all 
employed to control pests that threaten food production, 
namely weeds, insects, fungi and pathogens. Oftentimes, 
groups opposed to the use of these technologies in agri-
cultural production systems examine only the potential 
harms or downsides, such as the potential development 
of resistance, and do not consider the benefits of their use 
or the tradeoffs that are associated with precluding their 
use. It has been estimated that without pesticides 70  % 
of the world food crop would be lost and, even with pes-
ticide use, 42 % is destroyed by insects and fungal dam-
age [32]. Dispensing with pesticides would require at 
least 90 % more cropland to maintain present yields [33]. 
Likewise, the development of disease-resistant varieties 
of plants and animals is associated with potential harms, 
benefits and tradeoffs. Ironically, the tradeoffs associ-
ated with limiting or precluding the use of rDNA in the 
process of breeding disease-resistant animals are likely 
to include diminished animal welfare, decreased animal 
protein production, per animal thereby necessitating an 
increased number of animals to produce a given quantity 
of protein, and an increased use of antibiotics and other 
pesticides (e.g. insecticides) to help control animal dis-
eases around the world.
Perspective
The rDNA process-based governance of animal biotech-
nology is being increasingly questioned [34], and it is 
becoming difficult to justify given our increased under-
standing of genomes and the unfortunate fact that the 
current governance situation is resulting in the avoid-
ance or abandonment of potentially useful applications 
that could be enabled by these technologies. The lack of 
scientific certainty about any potential adverse effects 
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on biological diversity can be used to delay, or at worst 
permanently forestall, the adoption of potentially benefi-
cial LMOs produced using modern biotechnologies. The 
precautionary principle requires no assessment or judge-
ment of the potential benefits of a given modification, 
nor consideration of the opportunity costs associated 
with continuing to use existing animal genetic resources. 
This situation was perhaps most tersely summarized by 
Dr. Wells of the University of Missouri in Columbia in 
2013, “The basic premise for regulation appears to be that 
any genotype produced by breeding is safe, and that any 
genotype produced intentionally via rDNA technologies 
cannot be allowed to go to market” [35].
Further complicating these regulatory issues are newly-
available precision gene editing techniques that precisely 
mimic naturally-occurring evolutionary mutations, a 
process that can leave no DNA-based signature of modi-
fication in the genome to regulate. Recent review papers 
[36–38] summarize the use of site-specific designer 
nuclease genome editing techniques to improve livestock 
for agriculture. These methods are being used to explore 
a variety of approaches to address issues affecting animal 
agriculture. These include genetic research on generating 
offspring of a single sex for animal industries where one 
sex is favored (e.g. egg and dairy) [39, 40], development 
of genetic approaches for avoiding painful procedures 
such as dehorning and castration [40, 41] to improve ani-
mal welfare, and gene knockout approaches to preclude 
the production of endogenous proteins such as food 
allergens and prion proteins [42–44] to improve food 
safety. Many of these applications are directed towards 
improved animal welfare and again would seem to align 
with many definitions of sustainability. It is currently 
unclear whether these techniques, which do involve 
the “application of in  vitro nucleic acid techniques”, but 
frequently introduce genetic variation that is indistin-
guishable from naturally-occurring alleles induced by 
spontaneous mutation, will be subject to the modern bio-
technology regulatory governance, especially given there 
is often no rDNA sequence(s) present in the product.
Similarly, disease vectors are also being targeted with 
these techniques. Mosquitoes are known to transmit a 
number of pathogens that cause diseases such as yellow 
fever, dengue and chikungunya. Together, these infec-
tions are responsible for more than 50,000 human deaths 
each year. A recent report details the use of genome engi-
neering via the CRISPR-Cas9 system to generate stable 
germline mutations in the mosquito Aedes aegypti. The 
authors suggested that the techniques outlined in their 
paper could be useful not only for addressing the disease-
transmitting abilities of A. aegypti through a variety of 
mutant alleles, but also for modifying other non-model 
organisms [45].
Triggering governance and regulatory oversight based 
on the use of modern biotechnologies in the develop-
ment process, rather than on the outcomes or products 
resulting from the use of those technologies, is ineffective 
for addressing those risks that might be associated with 
non-governed processes and disadvantages governed 
technologies with unique regulatory burdens. If the risks 
and potential benefits resulting from a particular novel 
phenotype (e.g. disease-resistance) are the same, there 
would seem to be no rationale for regulating and increas-
ing the development and implementation costs of only 
those produced using specific techniques (e.g. rDNA) 
in the breeding program. Perhaps more importantly, in 
some cases the risks and ecological impacts associated 
with unregulated processes or existing production sys-
tems may in fact be greater than those associated with 
using systems that employ modern biotechnological 
approaches.
Even-handed, technology-agnostic evaluation of ani-
mal biotechnologies is essential to ensure that one strat-
egy is not chosen over another solely because it avoids 
onerous regulations. Regulation and governance to 
ensure the safety and responsible use of new technolo-
gies is necessary. However, such efforts should be pro-
portional to the unique risks posed by the product being 
evaluated, and should not be triggered on the technique 
or biotechnology that was used to produce those prod-
ucts. Currently, identical products produced using differ-
ent biotechnologies are subject to very different levels of 
scrutiny. It is perhaps this lack of logical consistency that 
most frustrates scientists working to develop new agri-
cultural technologies. It is time to carefully evaluate and 
weigh both any unique risks and potential benefits posed 
by novel traits developed in animal breeding programs, 
irrespective of the breeding method that was used to 
introduce those traits. Overly burdensome regulation of 
modern biotechnologies is forestalling the development 
of solutions to real-world agricultural problems.
Conclusion
The stated objective of the Cartegena Protocol is “the 
conservation and sustainable use of biological diversity”. 
However, as it is written it only covers transboundary 
movements of “living modified organisms” produced 
using specific modern biotechnologies, and considers 
only the potential risk associated with such develop-
ments. It ignores the fact that novel organisms created by 
traditional breeding and selection techniques may pose 
equivalent or greater risk, and also the opportunity costs 
associated with the delayed adoption of beneficial prod-
ucts that have been shown to be safe. And because the 
trigger is defined as a specific subset of biotechnologies, 
the definition may become outdated as technologies to 
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make subtle changes to the genome evolve. Good pub-
lic policy requires that regulation be clearly targeted to 
address an identified problem. Modern biotechnologies 
have not proven to be uniquely risky, and it is the attrib-
utes of the resulting organism that present both potential 
risks and benefits, regardless of the technology that was 
used to develop that organism.
The concern with the current governance of animal 
biotechnologies is that it actually results in an illogical 
incentive to pursue those technical approaches that are 
exempt from regulatory oversight, irrespective of the 
relative technical feasibility, likelihood of success, speed, 
potential harms, and potential benefits. A less effective, 
non-regulated approach may be preferred to a more 
precise, effective, and efficient regulated approach. In a 
world facing burgeoning demands for animal-source pro-
tein, creating arbitrary regulatory hurdles for potentially 
beneficial uses of modern animal biotechnologies based 
solely on their use of in vitro nucleic acid techniques can-
not be justified scientifically, and is hindering the devel-
opment of more productive animal agricultural systems 
globally.
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